As shown in Fig. 3D and 3F, compared with those in the CIS group, the levels of GRP78, XBP1s and CHOP were significantly increased (Figure S1J) in the UFL1 knockdown + cisplatin group and a similar trend was observed in the ratios of BAX/BCL-2 and cleaved caspase 3/caspase 3 (Figure S1K). Here, BCL2 is linked to in situ carcinoma.